

Progress report 2022

Health Economy and Society Policy

Project Professor: Tomoyuki Takura, Ph.D, MEng.

Project Lecturer: Seika Horiuchi, MD

Homepage <http://plaza.umin.ac.jp/hehp/>

■ Introduction and Organization

Health Economy and Society policy is a donated fund course established in 22nd Century Medical and Research Center in February 2017, which is donated by 10 companies, Development Bank of Japan Inc., Chugai Pharmaceutical Co., Ltd., Baxter Limited, Nihon Medi-Physics Co., Ltd., Medibrain Corporation, Asahi Kasei Medical Co., Ltd., NIPRO Corporation, Toray Medical Co., Ltd., JMS Co., Ltd., and Terumo Corporation, and is cooperating with Department of Cardiac Surgery, Division of Nephrology and Endo-cri-nology, and Department of Clinical Epidemiology & Health Economics as cooperating course. Also, in February 2023, this course was transferred to a social collaboration course by NN Life Insurance Co., Ltd. We are also exploring the mechanism of adherence and researching its socioeconomic impact with Department of Neuropathology, Department of Clinical Epidemiology & Health Economics as new cooperative courses.

The social structure has been changing over recent years and it can be assumed that policies related to the medical system and medical industry are at a crossroads in Japan and may undergo dramatic changes in the future. Our department was established to discuss future healthcare systems (medical practices and systems, economy and industry), particularly in terms of theory construction and validation studies pertaining to the "evaluation of the value of the healthcare field" and other topics.

Concretely, we promote theoretical and methodological research on health technology assessment, cost effectiveness analysis, and the

healthcare industry structure, and aim to evaluate the value of healthcare technologies and healthcare systems. We also promote manpower training programs (Program for "The movements of medical value") in health technology assessment with collaboration departments.

■ Research activities

We are engaging in the following research in order to promote rational and evidence-based medical resource investment, to support medical practice, and to promote advances in medical technology.

- 1) The evaluation of the cost effectiveness of various therapies, including (but not limited to) VAD therapy for severe heart failure, hemodialysis therapy for end-stage renal failure and radiological diagnostics.
- 2) A study of the socioeconomic on the disease burden impact of lifestyle-related diseases and dementia in Japan.
- 3) Testing and developing methods for evaluating labor productivity (e.g., the productivity of cardiology doctors) by applying data envelopment analysis (DEA) techniques.
- 4) Apply AI (artificial intelligence, machine learning) to develop a disease management program that focuses on adherence.

In this year, we have proceeded with the cost-effectiveness analysis of medical technology such as therapeutic devices for fulminant myocarditis and therapeutic agent for Kawasaki disease. In addition, we conducted the healthcare economics analysis of universal health coverage, as well as an analysis of regional function

cooperation of medical and nursing care.

Moreover, we conducted an analysis of the impact of renal transplantation on the medical insurance system, as well as the theory construction, cost calculation, and claim level estimation of medical treatment prices for the area of childbirth. We also verify the QOL measurement method (surrogate answer) for end-stage lung cancer.

We conducted health technology assessment (HTA) and data science education that applied the big data of the medical economy system (The Tokyo University Health Economy Big Data: *TheBD*). In addition, we are also working on a project to develop a forecasting model for HTA that makes use of the big data. Moreover, we are starting a study that applies computational finance to forecast the market value of research and development projects.

■ References

- 1) Tomoyuki Takura, Minoru Ono, Junya Ako, Yuji Ikari, Koichi Toda, Yoshiki Sawa; ETICA Study Investigators. Clinical and Economic Evaluation of Impella Treatment for Fulminant Myocarditis - A Preliminary Retrospective Cohort Study in Japan. *Circ J.* 2022 Nov 23. doi: 10.1253/circj.CJ-22-0439. Online ahead of print. (IF, 3.350; 2.540)
- 2) Hiroki Sugimori, Maki Hirao, Ataru Igarashi, Hiroshi Yatsushashi, Shunya Ikeda, Naohiko Masaki, Hiroshi Yotsuyanagi, Takeshi Yoda, Takeshi Odajima, Tomoyuki Takura, Tomohiro Hirao. Health state utilities of patients with hepatitis B and C and hepatitis-related conditions in Japan. *Sci Rep.* 12(1):17139. 2022. doi: 10.1038/s41598-022-21470-3. (IF, 4.379; 5.133)
- 3) Tetsuya Shiina, Keiko Goto-Hirano, Tomoyuki Takura, Hiroyuki Daida. Cost-effectiveness of follow-up invasive coronary angiography after percutaneous coronary stenting: a real-world observational cohort study in Japan. *BMJ Open.* 12(8):e061617. 2022. doi: 10.1136/bmjopen-2022-061617. (IF, 3.007; 2.86)
- 4) Tomoyuki Takura, Sayaka Horiuchi. Cost-effectiveness analysis of infliximab for the treatment of Kawasaki disease refractory to the initial treatment: A retrospective cohort study. *Journal of Cardiology.* 80(2):172-178. doi: 10.1016/j.jjcc.2022.03.005. 2022. (IF, 3,159)
- 5) Tomoyuki Takura, Hiroko Miura. Socioeconomic Determinants of Universal Health Coverage in the Asian Region. *Int. J. Environ. Res. Public Health.* 2022; 19(4):2376. <https://doi.org/10.3390/ijerph19042376>. (IF, 3,390; 3.531)
- 6) Tomoyuki Takura, Tomoko Koike, Yoko Matsuo, Asuko Sekimoto, Masami Mutou. Proxy Responses Regarding Quality of Life of Terminal Lung Cancer Patients: preliminary results from a prospective observational study. *BMJ Open.* 12(2):e048232. doi: 10.1136/bmjopen-2020-048232. 2022. (IF, 2.692; 2.981)
- 7) Kazuhiko Ikeuchi, Kazuya Okushin, Makoto Saito¹, Eisuke Adachi¹, Takeya Tsutsumi, Tomoyuki Takura, Hiroshi Yotsuyanagi. Prevalence of HIV infection among non-elderly individuals with hepatitis C in Japan: A population-based cohort study using a health insurance claim data. *BMC Infectious Diseases.* 22(1):167. doi: 10.1186/s12879-022-07152-5. 2022. (IF, 3.090; 3.401)
- 8) Study Protocol of Cardiac Rehabilitation for Acute Myocardial Infarction From the JROAD/JROAD-DPC Database — JROAD-CR —. Yasunori Suematsu, Shin-ichiro Miura, Akira Minei, Yoko Sumita, Koshiro Kanaoka, Michikazu Nakai, Hisatomi Arima, Koshi Nakamura, Tomoyuki Takura, Kazunori Shimada, Hirokazu Shiraishi, Nagaharu Fukuma, Yusuke Ohya, Shigeru Makita. *The JROAD-CR Investigators. Circulation Reports.* 5 (2): 62-65. 2023. (IF, -)
- 9) JCS/JACR 2021 Guideline on Rehabilitation in Patients With Cardiovascular Disease. Shigeru Makita, Takanori Yasu, Yoshihiro Akashi, Hitoshi Adachi, Hideo Izawa, Shunichi Ishihara, Yoshitaka Iso, Hideo Ohuchi, Kazuto Omiya, Yusuke Ohya, Koichi Okita, Yutaka Kimura, Akira Koike, Masahiro Kohzaki, Shinji Koba, Masataka Sata, Kazunori Shimada, Tomoki Shimokawa, Hirokazu Shiraishi, Naokata

Sumitomo O, Tetsuya Takahashi , Tomoyuki Takura , Hiroyuki Tsutsui , Masatoshi Nagayama , Emiko Hasegawa , Yoshihiro Fukumoto , Yutaka Furukawa , Shin-Ichiro Miura , Satoshi Yasuda , Sumio Yamada O, Yuichiro Yamada , Dai Yumino , Toshiko Yoshida , Takuji Adachi , Toshimi Ikegame , Kazuhiro P Izawa , Takeshi Ishida , Neiko Ozasa , Naohiko Osada , Hiroaki Obata O , Naoya Kakutani , Yusuke Kasahara , Masaaki Kato , Kentaro Kamiya , Shintaro Kinugawa , Yuji Kono , Yasuyuki Kobayashi , Teruyuki Koyama , Kazuhiro Sase , Shinji Sato O, Tatsuhiko Shibata , Norio Suzuki , Daisuke Tamaki , Minako Yamaoka-Tojo , Michio Nakanishi , Eisaku Nakane , Mari Nishizaki , Taiki Higo , Kanta Fujimi , Tasuku Honda , Yasuharu Matsumoto , Noriko Matsumoto , Ikuko Miyawaki , Makoto Murata , Shusuke Yagi , Masanobu Yanase O, Midori Yamada , Miho Yokoyama , Noboru Watanabe , Haruki Ito , Takeshi Kimura , Syunei Kyo , Yoichi Goto , Ryuji Nohara , Ken-Ichi Hirata ; Japanese Circulation Society/the Japanese Association of Cardiac Rehabilitation Joint Working Group. *Circ J.* 2022 Dec 9. doi: 10.1253/circj.CJ-22-0234. Online ahead of print. (IF, 3.350; 2.540)

10)Tomoyuki Takura, Issei Komuro, Minoru Ono. Trends in the cost-effectiveness level of percutaneous coronary intervention: Macro socioeconomic analysis and health technology assessment. *J Cardiol.* 2022 Sep 28;S0914-5087(22)00243-X. doi: 10.1016/j.jjcc.2022.09.011. Online ahead of print. (IF, 3,159)

11)Tomoyuki Takura, Naotsugu Ichimaru, Atushi Aikawa. “Health Economics of Renal Replacement Therapy”. *Updates on Renal Replacement Therapy.* London, IntechOpen; in press (ISBN 978-1-83769-175-3)

12)Tomoyuki Takura. “Socio-Economic Considerations of Universal Health Coverage: Focus on the Concept of Health Care Value and Medical Treatment Price”. *Health Insurance.* London, IntechOpen; 1-34. 2022 (DOI: 10.5772/intechopen.104798)

13)Tomoyuki Takura, Nitta Kousaku. Long-term effects of contrast-enhanced intervention on

progression of chronic kidney disease: A retrospective cohort study. *Kidney International Reports,* 7(2):SUPPLEMENT, S139-S140, 2022. (IF, 4.164; 4.196)

■ Lecturers

1) Tomoyuki Takura, Kosaku Nitta. Long-term effects of contrast-enhanced intervention on progression of chronic kidney disease: A retrospective cohort study. *ISN World Congress of Nephrology 2022 (WCN'22),* Kuala Lumpur, Malaysia, 2022.